inal studies to identify risk factors for
progression of C2 to C4 disease.

5.

Comparative studies of thermal vs nonthermal ablations.

6.

Studies to identify patients who need periprocedural
thrombosis prophylaxis and deÔ¨Åne optimal drugs
(LMWH, DOACs), dose, and duration of prophylaxis.

7.

Cost and QOL comparisons between staged vs
concomitant phlebectomy after saphenous ablation